The Pfizer vaccine recorded a 94% drop in symptomatic cases of COVID-19 in Israel

There are indications of a 94% reduction in symptoms of COVID-19 among 600,000 people who received two doses of Pfizer vaccine in the largest Israeli study to date.

According to a Reuters report, “Health Maintenance Organization (HMO) Clalit, which covers more than half of all Israelis, said the same group was 92% less likely to develop a severe disease than the virus. “

READ: COVID-19: Evidence suggests new variants could challenge vaccines

What are they saying

In words Ran Balicer, Clalit’s chief innovation officer,,

  • “It unequivocally shows that Pfizer’s coronavirus vaccine is extremely effective in the real world a week after the second dose, just as found in a clinical study.
  • “The data show that the Pfizer vaccine, which was developed in partnership with Germany’s BioNTech, is even more effective two weeks or more after the second shot.”

READ: Covid-19: Travel agencies recorded sales loss of 46.9% in 2020 – NANTA

According to Reuters, “Researchers from the Weizmann Institute of Science, who collected national data, said on Sunday that for the first time a sharp drop in hospitalizations and serious illnesses identified earlier was seen among the first age group to be vaccinated – aged 60 or older in those older than 55 years.

What you should know

  • It is important to note that hospitalizations and serious illnesses were still growing in the younger groups who started vaccination weeks later.
  • Israel is implementing a rapid introduction of the vaccine and its database offers insight into the effectiveness of the vaccine and at what point countries could acquire herd immunity.
  • To date, Israel has reported a total of 724,000 cases, 664,000 recoveries and 5,388 deaths.